30.04.2012 - The acquisition of Genzyme shows its benefits: Sanofi reported strong
sales and earnings growth in the first quarter of 2012.
Paris – The French drug maker reported a net profit of €1.8bn, up from €1.2bn in the first quarter of 2011. The better earnings, however, were not enough to change the company's gloomy outlook for the coming year. The executives warned that earnings in the rest of the year would be hit by the loss of US market exclusivity of its blood thinner Plavix (clopidogrel) in May, and blood pressure drug Avapro (irbesartan) at the end of March. Net sales rose more than 9% to €8.5bn, with revenue at the flagship pharmaceutical division, increasing 8.8% at constant exchange rates, to €7.32bn.
Genzyme contributed €841m. Sanofi benefited from growth in emerging markets (+9.9% to €2.6bn), with Brazil, Russia, Indian and China together contributing €917m. Sanofi's diabetes franchise also increased by 14.4% to €1.3bn. The contribution of Lantus (insulin glargine) is €1.1bn (+17.2%), which means it is the company's top-selling drug. Sanofi's oncology business grew by 12.8% to €741m, with Eloxatin (oxaliplatin) generating €321m in the US.
Sanofi's CEO Chris Viehbacher emphasised that the patent loss of former key products like Plavix and Avapro had been something the French multinational had long foreseen. According to Viehbacher, the company is now entering the final phase of its patent cliff. He said that Sanofi had built six "growth platforms" to replace sales lost to generic competition and generate sustainable growth. He noted that these new products would not be dependent on patents to the same extent. Growth platform businesses include Genzyme developments – including rare disease products like Cerezyme and Fabrazyme, plus the late-stage multiple sclerosis products Aubagio (teriflunomide) and Lemtrada (alemtuzumab). Other growth platforms are diabetes, vaccines, consumer health care, animal health, new products and emerging markets.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.
12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.